Hemorrhage, Surgical, Tonsillar Bleeding
Conditions
Keywords
Tranexamic Acid, Nebulizer, Post tonsillectomy hemorrhage
Brief summary
After a child has their tonsils removed, sometimes they might bleed which can be a problem. There is a special mist medicine called nebulized tranexamic acid (TXA) that might help stop the bleeding without having to touch the sore spot. If this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. Not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.
Detailed description
The study intervention involves administering nebulized tranexamic acid (TXA) to pediatric patients with traumatic hemorrhage (PTH). The intervention consists of three consecutive doses of nebulized TXA. The dosage of nebulized TXA is adjusted based on the child's weight. For children weighing more than 25 kg, each dose is 500 mg. For children weighing less than 25 kg, each dose is 250 mg. Frequency: The three doses of nebulized TXA are administered consecutively over the course of approximately an hour. Administration Method: Nebulized TXA is delivered through a nebulizer device. A nebulizer converts the liquid medication into a fine mist or aerosol, which is then inhaled by the patient. This method allows the medication to be delivered directly to the respiratory tract, where it can exert its effect on the bleeding site. Delivery Setting: The intervention may take place in a clinical setting, such as a hospital or outpatient clinic, where nebulizer devices and medical supervision are readily available. Each patient receives three nebulized independent doses of TXA in succession. The delivery of the intervention is carried out by healthcare professionals trained in administering nebulized medications.
Interventions
Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
OTHERNormal Saline
Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
Sponsors
The University of Texas Health Science Center at San Antonio
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
To maintain blinding, all personnel except the investigational pharmacist and/or statistician will be unaware of the administered drug. The randomization schedule will be pre-determined by a central randomization process and prepared as "use next boxes" to streamline the process at enrollment
Intervention model description
Two arm randomized, double-blind, controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Received a tonsillectomy 2. Presents to the ED with secondary\* post-tonsillectomy hemorrhage 3. Children between age of 2 to 17 years of age (i.e., before their 18th birthday) \*Secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery/PACU).
Exclusion criteria
1. Known and documented bleeding or clotting disorder. 2. Known pregnancy. 3. Patients with known hypersensitivity or allergic response to tranexamic acid. 4. Parents or guardians who cannot communicate in English or Spanish. 5. Intubation prior to enrollment. 6. Previously enrolled patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients enrolled per month | Baseline to 18 months (or duration of study approximately 18 months) | Assess target enrollment of patients per site per month. |
| Number of nebulizations per patient | Baseline to 18 months (or duration of study approximately 18 months) | Evaluate the ability to nebulize at least two doses of TXA to children with PTH |
| Indirect local concentration of nebulized TXA | Immediately post nebulizer treatment (within 60 minutes) and then within 8 hours. | Limited data on nebulized TXA systematic absorption. Topical PK studies of TXA document a significant reduction in systematic levels but the same hemostasis effect. Collection of two blood samples from each participant. This will verify a pulmonary physiological-based PK model (PBPK) (i.e., nasal cavity, pharynx, and lung) that indirectly predicts the oropharyngeal and systematic concentration of nebulized TXA. |
| Systemic Concentration of nebulized TXA | Immediately post nebulizer treatment (within 60 minutes) and up to eights hours. | Pharmacokinetics samples will be collected after completion of the last nebulized treatment received within sixty minutes. A second time point should then be collected after sixty minutes up to eight hours from last nebulization, separated from the previous time point by at least sixty to ninety minutes. The serum TXA levels will be used to verify a TXA Physiological-based Pharmacokinetic model and determine the population variability. This PBPK model is built by our research pharmacist based on extensive research already completed on TXA distribution and metabolism. Once the model is built, the investigators only need a one to two samples to determine if the model accurately reflects collect samples. The investigators will develop a base model to determine a best-fit compartmental model, distribution, and elimination kinetics. The investigators will also use stochastic models to evaluate between-subject variability in PK parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of return visits to the OR | Baseline to 18 months (or duration of study approximately 18 months) | The need for return to the Operating Room (OR) for surgical management of PTH) will be followed for up to seven days after randomization |
| Estimated blood loss | Baseline to 7 days | Determine the estimated blood loss per participant |
| Number of recurrences of PTH | Baseline to 18 months (or duration of study approximately 18 months) | Number of participants in which there was a recurrence of post-tonsillectomy hemorrhage after the study drug was administered |
| Number of blood transfusions required | Baseline to 18 months (or duration of study approximately 18 months) | Blood product transfusion volume will be measured at discharge or 24 hours (whichever comes first). This will include the volume of packed red blood cells, platelets, plasma, cryoprecipitate, or whole blood. Any mention of blood loss in electronic health records from emergency, anesthesiology, or surgeons' notes will be recorded. |
Countries
United States
Contacts
CONTACTAndrew D Meyer, MD, MS
CONTACTStephanie Perez, MHA
PRINCIPAL_INVESTIGATORAndrew D Meyer, MD, MS
The University of Texas Health Science Center at San Antonio
Outcome results
None listed